Immunotherapy in first-line treatment of recurrent non-small cell lung cancer
For a long time, the standards of first-line drug therapy for patients with advanced non-small-cell lung cancer (NSCLC), excluding cases of mutations of EGFR, ALK and ROS1, were platinum-containing regimens. However, the chemotherapeutic regimes used in the therapy of the first line therapy of NSCLC...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2019-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/5298 |